GT200000155A - Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1. - Google Patents

Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.

Info

Publication number
GT200000155A
GT200000155A GT200000155A GT200000155A GT200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A
Authority
GT
Guatemala
Prior art keywords
morby
compositions
methods
release
treatment
Prior art date
Application number
GT200000155A
Other languages
English (en)
Spanish (es)
Inventor
Bruce Henry Littman
Thasia Louise Goodwin Woodworth
Mark Anthony Dombroski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000155A publication Critical patent/GT200000155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
GT200000155A 1999-09-14 2000-09-14 Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1. GT200000155A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
GT200000155A true GT200000155A (es) 2002-03-08

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000155A GT200000155A (es) 1999-09-14 2000-09-14 Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.

Country Status (13)

Country Link
EP (1) EP1214087A1 (fr)
JP (1) JP2003509378A (fr)
AR (1) AR033650A1 (fr)
AU (1) AU6464400A (fr)
BR (1) BR0014003A (fr)
CA (1) CA2383026A1 (fr)
CO (1) CO5190701A1 (fr)
EC (1) ECSP003652A (fr)
GT (1) GT200000155A (fr)
PA (1) PA8502901A1 (fr)
PE (1) PE20010685A1 (fr)
TN (1) TNSN00183A1 (fr)
WO (1) WO2001019390A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619066B2 (en) 2004-04-02 2009-11-17 Amgen Inc. IL-1ra variants
WO2008129288A2 (fr) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides utiles dans le traitement de l'inflammation
EP3578547B1 (fr) * 2015-02-16 2021-05-26 The University of Queensland Sulfonylurées, composés apparentés, et leur utilisation
SG11201806745RA (en) 2016-02-16 2018-09-27 Univ Queensland Sulfonylureas and related compounds and use of same
WO2017184624A1 (fr) 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Composés et compositions pour traiter des états associés à une activité de nlrp
CA3047336A1 (fr) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
EP3634951A1 (fr) 2017-06-09 2020-04-15 Cadila Healthcare Limited Nouveaux composés de sulfoximine substitués
EP3649112A1 (fr) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
WO2019008025A1 (fr) 2017-07-07 2019-01-10 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US11203579B2 (en) 2017-07-24 2021-12-21 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
MX2020001778A (es) 2017-08-15 2020-03-24 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
WO2019166619A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2020010143A1 (fr) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Modulateurs de nlrp
PE20211049A1 (es) 2018-07-20 2021-06-04 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
EP3870565A1 (fr) 2018-10-24 2021-09-01 Novartis AG Composés et compositions pour traiter des états associés à l'activité des nlrp
EP3911631A4 (fr) 2019-01-14 2022-09-28 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
KR20230015418A (ko) * 2020-05-25 2023-01-31 베이징 브이디제이바이오 컴퍼니 리미티드 인터루킨-1 수용체 길항제 및 이를 포함하는 융합 단백질

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
WO1998032733A1 (fr) * 1997-01-29 1998-07-30 Pfizer Inc. Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée

Also Published As

Publication number Publication date
PE20010685A1 (es) 2001-07-03
JP2003509378A (ja) 2003-03-11
EP1214087A1 (fr) 2002-06-19
AU6464400A (en) 2001-04-17
TNSN00183A1 (fr) 2005-11-10
WO2001019390A1 (fr) 2001-03-22
CO5190701A1 (es) 2002-08-29
AR033650A1 (es) 2004-01-07
PA8502901A1 (es) 2002-02-21
CA2383026A1 (fr) 2001-03-22
BR0014003A (pt) 2002-05-21
ECSP003652A (es) 2002-04-23

Similar Documents

Publication Publication Date Title
GT200000155A (es) Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.
EP4310082A3 (fr) Azolopyrimidine pour le traitement de troubles liés au cancer
BRPI0017013B8 (pt) composição de antibiótico azalídeo e método para sua obtenção
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
ES2192035T3 (es) Agentes anti-inflamatorios que presentan una selectividad para los glucocorticoides.
ECSP088752A (es) Formulaciones para administración parenteral de compuestos y sus usos
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
AR048912A1 (es) Inmunoglobulinas anti-nogo
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
UY28222A1 (es) Inhibidores de citoquinas
ES2194567B1 (es) Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas.
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
UY29673A1 (es) Derivados sustituidos de 6-(4-clorofenil) tieno (3,2,d)- pirimidin- 4(3h)-ona y (1,2,3,)-triazin-4-(3h)-ona,composiciones farmaceuticas conteniéndolos, procesosde peparación y aplicaciones.
AR058561A1 (es) Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco
UY37813A (es) Derivados de pirrolopiridina sustituidos
ECSP056006A (es) Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas
AR057239A1 (es) Inmunoglobulinas
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
BR9608594B1 (pt) misturas de benzimidazóis substituìdos para o combate de protozoários parasìticos.
DK0710239T3 (da) Nye 9-N-bicycliske nucleosidmidler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner